

Haematologica
HAEMATOL/2016/159905
Version 4

Hyper-CVAD + epratuzumab as salvage regimen for younger patients
with relapsed/refractory CD22+ precursor B-cell ALL.

Patrice Chevallier, Sylvain Chantepie, Françoise Huguet, Emmanuel Raffoux, Xavier Thomas, Thibaut Leguay, Tony Marchand, Françoise Isnard, Aude Charbonnier, Sébastien Maury, Maria-Pilar Gallego-Hernanz, Nelly Robillard, Thierry Guillaume, Pierre Peterlin, Alice Garnier, Fanny Rialland, Claire Le Houerou, David M. Goldenberg, William A. Wegener, Marie-C Béné, and Hervé Dombret
(Collaborative Groups: GRAALL)

Disclosures: Drs. Wegener and Goldenberg are senior employees with stock or stock options in Immunomedics; Dr. Goldenberg also is a patent inventor of epratuzumab. All other authors declare no potential financial conflicts.

Contributions: PC designed, performed, and coordinated the research, collected, analyzed, interpreted the data, and wrote the manuscript. NR performed flow cytometry analyses and commented on the manuscript. MCB performed statistical analyses, produced the figures, and commented on the manuscript. W.A. Wegener and D. M. Goldenberg provided epratuzumab, and revised the manuscript. SC, FH, ER, XT, TL, TM, FI, AC, SM, MPGH, TG, PP, AG, FR, CLH and HD included patients, contributed data and commented on the manuscript.